| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mohamed A Schumann, Aurélie Gaasch, Sandra Boyaci, Frederik Fuchs, Franziska Walter, Sebastian N Marschner, Chukwuka Eze, Christoph Benedikt Westphalen, Julian Walter Holch, Georg Beyer, Wolfgang G Kunz, Julia Mayerle, Maximilian Niyazi, Claus Belka, Stefanie Corradini and Paul Rogowski |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed A Schumann, Department of Radiation Oncology, LMU University Hospital, Marchioninistrasse 15, Munich 81377, Germany. mohamed.schumann@med.uni-muenchen.de |
| Key Words |
Pancreatic cancer; Pancreatic ductal adenocarcinoma; Radiotherapy; Stereotactic body radiotherapy; Metastatic pancreatic ductal adenocarcinoma; Magnetic resonance-guided radiotherapy |
| Core Tip |
Local progression of the primary tumor remains a major cause of morbidity in metastatic pancreatic ductal adenocarcinoma, even in the era of modern chemotherapy. This prospective observational study demonstrates that five-fraction stereotactic magnetic resonance-guided radiotherapy to the primary tumor is feasible and safe in patients with metastatic pancreatic ductal adenocarcinoma, achieving good local control, meaningful pain palliation, and low rates of high-grade toxicity. These findings support magnetic resonance-guided radiotherapy as a promising local treatment option within multimodal strategies for carefully selected patients with controlled metastatic disease. |
| Publish Date |
2026-07-17 08:23 |
| Citation |
Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, Eze C, Westphalen CB, Holch JW, Beyer G, Kunz WG, Mayerle J, Niyazi M, Belka C, Corradini S, Rogowski P. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World J Gastroenterol 2026; 32(29): 117832
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i29/117832.htm |
| DOI |
https://doi.org/10.3748/wjg.117832 |
